MedPacto, Inc. and OncoVenture have submitted IND application to US FDA for Medpacto's oral ALK5 inhibitor, TEW-7197.
Apr 03, 2014EVENTSHit 2022
On March 25th 2014, MedPacto, Inc. and OncoVenture (NOV, Director: Dr. In-Chul Kim) have submitted an investigational new drug (IND) application to the US Food and Drug Administration (FDA) for its TEW-7197, an oral ALK5 inhibitor targeting solid tumor indications. Medpacto, Inc. a spun-off company from Theragen Etex Co to focus on developing TEW-7197. TEW-7197 had been supported by the Program for Disease-Based Discovery of Global New Drug Candidates.
|Previous||Announcement: An annual general meeting of stockholders|